01/24/22 7:30 AMNasdaq, NYSE : ARWR, GSK Arrowhead Pharmaceuticals Announces Closing of Agreement with GlaxoSmithKlineArrowhead Pharmaceuticals Inc. today announced that the exclusive license agreement between Arrowhead and GlaxoSmithKline announced on November 22, 2021, has now closed. Closing of the transaction was subject to customary closing conditions and expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as...RHEA-AIneutral
01/21/22 10:22 AMNYSE : GSK Routine Vaccination Rates in Teens and Adults Continue to Lag Behind Pre-Pandemic Levels, Follow-up Analysis ShowsCenters for Disease Control and Prevention- recommended vaccinations for teens and adults continued to lag in 2020 and into the summer of 2021, according to a follow-up claims analysis commissioned by GSK and conducted by Avalere Health, an Inovalon company. “It's very concerning to continue to see millions of missed CDC- recommended vaccinations among both...RHEA-AIvery negative
01/07/22 7:00 AMNasdaq, NYSE : MASS, GSK low float908 Devices Announces GSK Purchases Fifth REBEL Cell Culture Media Analyzer908 Devices, a pioneer of purpose-built handheld and desktop devices for chemical and biomolecular analysis, today announced that GlaxoSmithKline has purchased an additional REBEL™ cell culture media analyzer. Kevin J. Knopp, CEO and co-founder of 908 Devices.“ The REBEL analyzer enables our biopharma customers to make critical decisions on optimizing cell...RHEA-AIneutral
12/20/21 6:14 PMNYSE : GSK, PFE fda approvalViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV preventionViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, today announced that the US Food and Drug Administration approved Apretude, the first and only long-acting injectable pre-exposure prophylaxis option to reduce the risk of sexually acquired HIV-1.RHEA-AIneutral
11/30/21 7:01 PMNYSE : PFE, GSK Forty Years on From the Start of the HIV Epidemic, New Data Reveals People Living With HIV Face Outdated Attitudes and Ongoing DiscriminationFunded by ViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline Plc, with Pfizer Inc. and Shionogi Limited as shareholders, the survey uncovers outdated attitudes and inherent bias amongst the general public towards people living with HIV. An overwhelming majority of respondents believe there are still negative...RHEA-AIneutral
11/22/21 4:00 PMNasdaq, NYSE : ARWR, GSK Arrowhead Pharmaceuticals Enters Exclusive License Agreement with GSK for ARO-HSDArrowhead Pharmaceuticals Inc. today announced that it entered into an exclusive license agreement with GlaxoSmithKline under which GSK will develop and commercialize ARO-HSD, Arrowhead’ s investigational RNA interference therapeutic in a Phase 1/ 2 trial that is currently being developed as a treatment for patients with nonalcoholic...RHEA-AIpositive
11/17/21 9:07 AMNYSE : GSK Robitussin Teams Up with Tony Award-Winning Actress, Adrienne Warren, to Help Increase Access to the Performing Arts in Underserved CommunitiesGSK Consumer Healthcare's (LSE/NYSE: GSK) Robitussin brand today announced a partnership with the All Stars Project, Inc. to help provide access to performing arts education for youth in underserved communities. Robitussin believes that everyone has aRHEA-AIpositive
11/15/21 11:20 AMNYSE : GSK TUMS® Provides #TUMSworthy Holiday Hacks for Heartburn Inducing Moments this Thanksgiving with the Help of Comedian Ronny ChiengGlaxoSmithKline (LSE: GSK) (NYSE: GSK) – This Thanksgiving, bring more holiday cheer and less heartburn fear to the table. As friends and family come back together again to celebrate this holiday season, TUMS®, America's #1 heartburn brand, is partneringRHEA-AIneutral
11/05/21 3:46 PMNYSE : GSK GSK announces positive Phase III efficacy and safety data for daprodustat in patients with anaemia due to chronic kidney diseaseGlaxoSmithKline plc (LSE/NYSE: GSK) today announced positive results from the Phase III ASCEND (Anaemia Studies in Chronic Kidney Disease: Erythropoiesis via a novel prolyl hydroxylase inhibitor Daprodustat) programme for daprodustat, an investigational oralRHEA-AIneutral
10/28/21 3:13 AMNYSE : PFE, GSK ViiV Healthcare announces European Commission Decision for Vocabria (cabotegravir) and Rekambys (rilpivirine) injections to be initiated with or without an oral lead-in period for the long-acting treatment of HIVViiV Healthcare, the global specialist HIV company majority owned by GlaxoSmithKline plc, with Pfizer Inc. and Shionogi Limited as shareholders, announced that the European Commission has granted a decision to update the Summary of Product Characteristics for Vocabria and Janssen Pharmaceutical Companies of Johnson& Johnson’ s Rekambys giving...RHEA-AIneutral
